Skip to main content
main-content

22-09-2020 | Lung cancer | Video

ESMO 2020 | PRINCEPS data point to feasibility of neoadjuvant atezolizumab in NSCLC

Benjamin Besse outlines phase 2 trial results supporting the further investigation of neoadjuvant atezolizumab followed by surgery in individuals with resectable non-small-cell lung cancer (3:40).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits